{"prompt": "['CANOPY GROWTH', 'Protocol #710-4502', 'The Sponsor will perform statistical analyses. The Sponsor or designee will extract and analyze', 'descriptive data every 6 months. This will be done to keep sites apprised of study progress. A de-', 'identified summary report will be generated and delivered to all registered site physicians.', 'The report will indicate:', 'The number of physician-collaborators stratified by country.', 'The number of subjects enrolled stratified by country.', 'Subject demographics, chronic pain classification, and treatment goal.', 'Subject concomitant medication use.', 'Subject ST treatment regimens.', 'Incidence of AEs per individual ST product.', 'Upon database lock a series of analysis will be conducted to address study objectives. For each analysis,', 'the normality of the data distributions will be ascertained using the Shapiro-Wilk test of normality and', \"Levene's test of equality of error variance. Descriptive statistics (frequencies, means, and standard\", 'deviations for normally distributed parametric data; medians and interquartile ranges for nonparametric', 'data) will be used to characterize the sample. Outcome analyses will include a change in ST regimen; a', 'change in reported opioid consumption in MME/day; change in daily dose of other medications,', 'including analgesics, sedatives, and benzodiazepines; change in responses to BPI-SF items and EQ-5DL', 'items; initial PGI-C and changes over time; and initial CGI-I and changes over time. For the safety', 'endpoint, AEs will be tabulated descriptively. Detailed analyses are outlined in the Statistical Analysis', 'Plan.', 'Number of Subjects (Planned):', 'Given a continuous enrollment design, the study will include two enrollment milestones over the 2-year', 'study period. Milestone 1, targeted for the end of year 1 will be to recruit 750 subjects. Milestone 2,', 'targeted for the end of year 2 will be to recruit 750 subjects. To enroll a total of up to 1500 subjects. The', 'number of subjects may vary based on the real-life use of ST products. Sites will be recruited from', 'countries where ST products are available: Canada, United Kingdom, Germany, and Australia. Sites', 'from additional countries may be included as ST products are rolled out in those countries and based on', 'site feasibility.', 'The present study has an observational design that poses low-burden for subjects, as the number and', 'frequency of in-clinic (telemedicine) visits represent those necessary for adequate monitoring of', 'treatment for chronic pain and at-home follow-ups will be completed using a simple online app and take', 'no longer than 15 minutes to complete. On this premise, we did not restrict the sample size based on an', 'estimated minimum required sample. Furthermore, the observational nature of the primary endpoint', '(daily average dose [in mg] of THC and CBD and mode of administration [inhaled or ingested]), did not', 'permit an a priori power analysis to estimate sample size. A sample size of 1500 subjects is consistent', 'with similar previous observational registry studies.', '25 November 2020', 'CONFIDENTIAL', 'Page 11 of 79']['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', 'Table 1.', 'Schedule of Events', 'Un-', 'Month 1', 'Month 2', 'Month 3', 'Month 4', 'Month 6', 'Month 8', 'Month 10', 'Month 12', 'Day 1', 'scheduled', '(+/-7d)', '(+/-7d)', '(+/-7d)', '(+/-7d)', '(+/-7d)', '(+/-7d)', '(+/-7d)', '(+/-7d)', 'visit', 'Physician', 'Subject-', 'Physician', 'Subject-', 'Physician', 'Subject-', 'Physician', 'Subject-', 'Physician', 'Baseline', 'verified', 'Follow-', 'verified', 'Follow-', 'verified', 'Follow-', 'verified', 'Follow-', 'Visit', 'Follow-', 'up 1', 'Follow-up', 'up 2', 'Follow-', 'up 3', 'Follow-up', 'up 4', 'up 1', '2', 'up 3', '4', 'Electronic Informed', 'X', 'consent form (eICF)', 'Pregnancy Test', 'X', 'Review eligibility', 'X', 'criteria check list', 'Create subject', 'X', 'REDCap Cloud', 'account', 'Demographics', 'X', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'medications', 'Chronic Pain', 'X', 'Classification', 'Cannabis experience', 'X', 'Treatment goal', 'X', 'ST treatment regimen', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Additional cannabis', 'X', 'X', 'X', 'X', 'consumption', 'BPI-SF\u00b9', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'EQ5D-5L\u00b2', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'PGI-C', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'CGI-I', 'X', 'X', 'X', 'X', 'X', 'Subject AE\u00b3 log', 'Physician AE\u00b3 form', 'X', 'X', 'ST discontinuation', 'X', 'assessment', 'Exit assessment', 'X', 'Abbreviations: AE, adverse event; BPI-SF, Brief Pain Inventory-Short Form; CGI-I, Clinical Global Impression-Improvement; PGI-C, Patient-', 'Global Impression of Change; eICF, electronic informed consent form; EQ5D-5L-European QoL; ST, Spectrum Therapeutics.', '1. The subject-verified visits will only include numeric rating scale pain items from the BPI.', '2. EQ5D-5L-QoL - (5 category questionnaires to be completed by the subject)', '3. AEs recorded by the subject at subject-verified follow-ups will be assessed by the physician at physician verified follow-up.', '25 November 2020', 'CONFIDENTIAL', 'Page 12 of 79']\n\n###\n\n", "completion": "END"}